4-((四氢-2H-吡喃-2-基)甲氧基)苯甲醛 | 1021232-09-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-((四氢-2H-吡喃-2-基)甲氧基)苯甲醛
• 英文名称: 4-((tetrahydro-2H-pyran-2-yl)methoxy)benzaldehyde
• 英文别名: 4-(Oxan-2-ylmethoxy)benzaldehyde
• CAS: 1021232-09-6
• 化学式: C₁₃H₁₆O₃
• mdl: MFCD11156472
• 分子量: 220.268
• InChiKey: FNPGITCUHYNIHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-((四氢-2H-吡喃-2-基)甲氧基)苯甲醛 在 sodium hydroxide 哌啶 、 sodium tetrahydroborate 、 N,N-二甲基甘氨酸 、 溶剂黄146 作用下， 以 四氢呋喃 、 水 、 甲苯 为溶剂， 反应 4.0h， 生成 5-[4-(Tetrahydro-pyran-2-ylmethoxy)-benzyl]-thiazolidine-2,4-dione
  参考文献：
  名称：

  Structure–activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium

  摘要：

  Depletion of calcium from the endoplasmic reticulum has shown to affect protein synthesis and cell proliferation. The anticancer effect of troglitazone was reported to be mediated by depletion of intracellular calcium stores resulting in inhibition of translation initiation. The unsaturated form of troglitazone displays similar anticancer properties in vitro. In this letter, we report our findings on the minimum structural requirements for both compounds to retain their calcium release and antiproliferative activities. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.087
• 作为产物：
  描述：

  四氢吡喃-2-甲醇 、 对氟苯甲醛 在 potassium tert-butylate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 4-((四氢-2H-吡喃-2-基)甲氧基)苯甲醛
  参考文献：
  名称：

  Structure–activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium

  摘要：

  Depletion of calcium from the endoplasmic reticulum has shown to affect protein synthesis and cell proliferation. The anticancer effect of troglitazone was reported to be mediated by depletion of intracellular calcium stores resulting in inhibition of translation initiation. The unsaturated form of troglitazone displays similar anticancer properties in vitro. In this letter, we report our findings on the minimum structural requirements for both compounds to retain their calcium release and antiproliferative activities. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.087

文献信息

• Isoxazol-5(4H)one Derivatives as PTP1B Inhibitors Showing an Anti-Obesity Effect
  作者：Bhooshan Kafle、Nilkanth G. Aher、Deegendra Khadka、Hwangseo Park、Hyeongjin Cho

  DOI：10.1002/asia.201100154

  日期：2011.8.1

  prepared in a day by using the present protocol. The library compounds thus obtained were examined for their inhibitory activities against PTP1B. Among them, compound C3 was the most potent inhibitor of PTP1B with an IC50 of 2.3 μM. The in vivo effect of C3 was also examined in an obesity‐prone mouse strain. Diet‐induced obese (DIO)/diabetic mice were divided into two groups and each group was fed a

  在开发治疗性目标酶的抑制剂中，大量的时间和精力致力于大量化合物的制备。为了开发一种有效的蛋白酪氨酸磷酸酶（PTP）1B抑制剂作为抗肥胖和/或抗糖尿病药，我们使用简化的程序构建了一个异恶唑酮化学库，该程序避免了繁琐的后处理和纯化步骤。10×7异恶唑酮衍生物是通过将两半目标化合物偶联而合成的。当在试管中混合并加热时，前体产生的反应产物为沉淀物。短暂洗涤后，产物纯度足以用于酶促实验。通过制备用于偶联反应的前体，可以使用本方案在一天之内制备10×7库化合物。检查由此获得的文库化合物对PTP1B的抑制活性。其中，复合C3是PTP1B的最有效的抑制剂，其IC 50为2.3μ中号。还对易肥胖的小鼠品系中的C3进行了体内研究。饮食诱导的肥胖（DIO）/糖尿病小鼠分为两组，每组喂养高脂饮食（HFD）或HFD + C3，持续4周。与喂食HFD的对照组相比，在喂食期的四个星期内，C3喂食的小鼠组的体重显着减少。
• NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF
  申请人：Cho Hoon

  公开号：US20110269954A1

  公开（公告）日：2011-11-03

  The present invention relates to novel thiazolidinedione derivatives expressed by the following formula (I) and the uses thereof. More specifically, the present invention relates to novel thiazolidinedione derivatives expressed by the following formula (I) and a pharmaceutical composition comprising the same. The novel thiazolidinedione derivatives of formula (I) according to the present invention can be effectively used for the prevention or treatment of cardiovascular disease, gastrointestinal disease and renal disease by inhibiting the activity of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) that decomposes prostaglandins as well as useful for the prevention of hair loss and the stimulation of hair growth, and osteogenic stimulation and wound healing.

  本发明涉及由以下式（I）表示的新型噻唑烷二酮衍生物及其用途。更具体地说，本发明涉及由以下式（I）表示的新型噻唑烷二酮衍生物以及包含其的药物组合物。根据本发明的式（I）的新型噻唑烷二酮衍生物可以通过抑制分解前列腺素的15-羟基前列腺素脱氢酶（15-PGDH）的活性，有效用于预防或治疗心血管疾病、胃肠道疾病和肾脏疾病，同时也用于预防脱发和促进头发生长，以及促进骨生成和伤口愈合。
• Isoxazolone Derivatives as Potent Inhibitors of PTP1B
  作者：Bhooshan Kafle、Hyeong-Jin Cho

  DOI：10.5012/bkcs.2012.33.1.275

  日期：2012.1.20
• US8637558B2
  申请人：——

  公开号：US8637558B2

  公开（公告）日：2014-01-28